We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+14.61%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$51.6B
AUM Growth
+$5.68B
Cap. Flow
-$429M
Cap. Flow %
-0.83%
Top 10 Hldgs %
17.19%
Holding
3,020
New
40
Increased
1,306
Reduced
1,586
Closed
73

Top Buys

Rank Stock Value
1
DIS icon
Walt Disney
DIS
+$73.8M
2
AMZN icon
Amazon
AMZN
+$68.6M
3
AAPL icon
Apple
AAPL
+$64.9M
4
MSFT icon
Microsoft
MSFT
+$61.4M
5
META icon
Meta Platforms (Facebook)
META
+$30.9M

Sector Composition

Rank Sector Weight
1 Technology 18.09%
2 Financials 15.13%
3 Healthcare 13.65%
4 Consumer Discretionary 10.39%
5 Industrials 10.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WSC icon
2326
WillScot Mobile Mini Holdings
WSC
$4.79B
$504K ﹤0.01%
45,420
+1,521
+3% +$15.8K
CSTE icon
2327
Caesarstone
CSTE
$73M
$502K ﹤0.01%
32,147
-240
-0.7% -$3.76K
PGEN icon
2328
Precigen
PGEN
$2.49B
$502K ﹤0.01%
95,349
-2,769
-3% -$19.2K
MRT
2329
DELISTED
MedEquities Realty Trust, Inc.
MRT
$502K ﹤0.01%
45,108
+20
+0% +$216
SENEA icon
2330
Seneca Foods Class A
SENEA
$1.15B
$501K ﹤0.01%
20,384
+458
+2% +$13K
IMGN
2331
DELISTED
Immunogen Inc
IMGN
$498K ﹤0.01%
183,673
-5,155
-3% -$22.3K
TPB icon
2332
Turning Point Brands
TPB
$1.7B
$496K ﹤0.01%
10,770
+635
+6% +$24.3K
GTHX
2333
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$495K ﹤0.01%
29,815
+1,569
+6% +$29.8K
ORC
2334
Orchid Island Capital
ORC
$1.29B
$494K ﹤0.01%
15,001
+203
+1% +$6.93K
RCUS icon
2335
Arcus Biosciences
RCUS
$3.59B
$494K ﹤0.01%
39,535
-307
-0.8% -$3.33K
BSRR icon
2336
Sierra Bancorp
BSRR
$533M
$493K ﹤0.01%
20,307
+388
+2% +$10.1K
BBBY
2337
Bed Bath & Beyond
BBBY
$430M
$491K ﹤0.01%
39,308
+2,217
+6% +$30.3K
FMNB icon
2338
Farmers National Banc Corp
FMNB
$939M
$490K ﹤0.01%
35,568
-190
-0.5% -$2.62K
MLR icon
2339
Miller Industries
MLR
$629M
$490K ﹤0.01%
15,884
+221
+1% +$6.85K
AKCA
2340
DELISTED
Akcea Therapeutics Inc
AKCA
$486K ﹤0.01%
17,159
+409
+2% +$11.9K
LFCR icon
2341
Lifecore Biomedical
LFCR
$175M
$483K ﹤0.01%
39,307
+884
+2% +$10.8K
SRGA
2342
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$482K ﹤0.01%
2,672
-36
-1% -$5.21K
VHC icon
2343
VirnetX Holding Corp
VHC
$65.6M
$481K ﹤0.01%
3,800
+116
+3% +$12K
FRPH icon
2344
FRP Holdings
FRPH
$413M
$479K ﹤0.01%
20,154
-170
-0.8% -$4.23K
ATEN icon
2345
A10 Networks
ATEN
$2.06B
$477K ﹤0.01%
67,228
+1,501
+2% +$10.2K
SWI
2346
DELISTED
SolarWinds Corporation Common Stock
SWI
$476K ﹤0.01%
23,136
+3,152
+16% +$59.1K
RILY icon
2347
BRC Group Holdings
RILY
$301M
$473K ﹤0.01%
28,338
-243
-0.9% -$3.87K
CIA icon
2348
Citizens
CIA
$234M
$469K ﹤0.01%
70,384
-742
-1% -$5.29K
CRBP icon
2349
Corbus Pharmaceuticals
CRBP
$181M
$469K ﹤0.01%
2,251
+95
+4% +$21K
ATEX icon
2350
Anterix
ATEX
$2.04B
$467K ﹤0.01%
13,293
-135
-1% -$5.31K

Similar funds

RhumbLine Advisers's Q1 2019 Portfolio in Review

As of Q1 2019, RhumbLine Advisers held 3,020 positions worth $51.6B, up 12% from $46B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Trading was light in Q1 2019: portfolio turnover was 3.7%. RhumbLine Advisers opened 40 new positions and exited 73, leaving the 3,020-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q1 2019 buy was Fox Class A: 602,636 shares worth $22.1M.
  • RhumbLine Advisers added most to Walt Disney in Q1 2019, an estimated $73.8M increase.
  • RhumbLine Advisers's biggest Q1 2019 reduction was Wells Fargo, cutting an estimated $16.4M.
  • RhumbLine Advisers fully exited Twenty-First Century Fox, Inc. Class A in Q1 2019, selling an estimated $89.7M.
  • RhumbLine Advisers's ten largest holdings make up 17% of its $51.6B portfolio in Q1 2019.
  • RhumbLine Advisers opened 40 new positions and closed 73 in Q1 2019.
  • RhumbLine Advisers's portfolio value rose 12% quarter-over-quarter to $51.6B.

Based on RhumbLine Advisers's 13F filing for Q1 2019, filed 1 May 2019.